<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167101</url>
  </required_header>
  <id_info>
    <org_study_id>08-62</org_study_id>
    <nct_id>NCT01167101</nct_id>
  </id_info>
  <brief_title>Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?</brief_title>
  <official_title>Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangdong Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet
      conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good
      effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized
      controlled study to assess the effect of a combination therapy of rebamipide and proton pump
      inhibitor (PPI) on post ESD ulcer healing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing efficacy of Rebamipide in the treatment of iatrogenic gastric ulcer</measure>
    <time_frame>at 2month after endoscopic submucosal dissection (ESD)</time_frame>
    <description>Healing efficacy will be assessed by the change of ulcer size. Quality of Ulcer Healing(QOUH) wil be assessed by nodularity in the healed ulcer by two endoscopist.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Stomach Ulcer</condition>
  <arm_group>
    <arm_group_label>Pantoprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>controls Pantoprazole 40mg qd for 28days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole + Rebamipde</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>Rebamipide 100mg Tid for 28days</description>
    <arm_group_label>Pantoprazole + Rebamipde</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole</intervention_name>
    <description>pantoprazole 40mg qd for 28days</description>
    <arm_group_label>Pantoprazole</arm_group_label>
    <arm_group_label>Pantoprazole + Rebamipde</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients underwent ESD for gastric adenoma or cancer

        Exclusion Criteria:

          -  subjects with previous gastric surgery

          -  subjects taking aspirin, anticoagulant, or antiplatelet agent

          -  subjects having malignancy except gastric cancer

          -  pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangdong Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Shin, Woon Geon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rebamipide</keyword>
  <keyword>gastric ulcer</keyword>
  <keyword>healing rate</keyword>
  <keyword>iatrogenic gastric ulcer after endoscopic submucosal dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

